Navigation Links
Advanced Life Sciences Announces Second Quarter 2008 Financial Results

Present posters and meet with National Advisory Board for

cethromycin at the October 25-28 ICAAC/IDSA conference in

Washington, DC;

* Under the DTRA contract, expand advanced studies of cethromycin as a

broad spectrum medical countermeasure;

* Continue preparing for commercial launch of cethromycin through

manufacturing, market research, medical education, and pricing

strategy activities;

* Dose first patient in ALS-357 PhaseI/II melanoma trial.

Financial Guidance for the Third Quarter of 2008

Advanced Life Sciences expects its third quarter 2008 cash requirements to fall in the range of $3.4 million and $3.7 million, leaving a cash balance of $5.4 million to $5.7 million as of September 30, 2008. Management believes that this cash balance will be sufficient to allow the Company to progress to the period in which it submits the NDA for cethromycin in the CAP indication to the FDA. To fund ongoing operations including the payment of any milestone payment due to Abbott Laboratories in connection with the submission of the cethromycin NDA, the Company intends to raise additional capital in 2008 through a commercial partnership and/or the sale of equity, if available at terms acceptable to us, which cannot be assured.

Conference Call Details

Advanced Life Sciences will host a conference call and live webcast at 10:00 a.m. Eastern Time on Thursday, August 14, 2008 to discuss the company's second quarter financial results.

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website Alternatively, callers may participate in the conference call by dialing 888-713-4218 (domestic) or 617-213-4870 (international). The passcode for the conference call is

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
(Date:10/7/2015)... Calif. , Oct. 7, 2015  ChromaDex ... wellness and nutritional ingredients that creates science-based solutions ... sports nutrition, and pharmaceutical products, today announced that ... , CEO and Founder, is now available for ...   -->   ...
(Date:10/7/2015)... , Oct. 7, 2015  October is National Liver ... has committed to donating a portion of its October ... and hepatology practices. ... in a variety of ways; whether it is by ... world, collaborating with researchers in different disease and investigation ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , ... Coatings to provide a comprehensive overview of the innovations in smart coatings using ... . This webinar will be given by Professor Roberto Advincula, professor with ...
(Date:10/7/2015)... ... October 07, 2015 , ... Tunnell Consulting , Inc. ... the Operational and Process Improvement practice. He brings to his role more than ... “I am delighted that Dr. Matzmorr is joining our team,” said Dr. Philippe Cini, ...
Breaking Biology Technology:
... Following the,establishment of their Industrial Management Board, ... is happy to announce its,official launch event to ... of M.B.N Nanomaterialia, the board members Mr Manfred ... Andrea Reinhardt of microTEC,look forward to a very ...
... Fame Coach Jim Calhoun Credits Early Diagnosis with ... two of AdvaMed 2007:,The MedTech Conference will highlight how ... technology as well as speakers on the,diversity and strength ... conference runs Oct. 1 through Oct. 3., Co-writing ...
... October 2 - Management and Distinguished ... Development Programs, as Well as on,the microRNA Field ... a global leader in,microRNA-based diagnostics and therapeutics, announced ... and their significant potential in cancer,treatment and other ...
Cached Biology Technology:
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
Breaking Biology News(10 mins):
... tissues into mice, researchers report in the November Cell ... normal and obese mice. The findings suggest that the hormone ... insulin resistance and type 2 diabetes. , Insulin resistance, in ... sugar (glucose) levels, is a precursor to diabetes. ...
... Cancer Symposium features the latest findings in laboratory, translational ... on new and promising therapeutic approaches, as well as ... To help you take the best advantage of ... you to visit to view the ...
... N.Y. (Mon., Nov. 3, 2008) Understanding the ... tissues requires experimental systems that allow for the study ... laboratory. This month,s issue of Cold Spring ... with detailed instructions for setting up these experimental culture ...
Cached Biology News:
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Biology Products: